Molecular Formula | C11H6ClN3O6.2C4H11NO3 |
Molar Mass | 553.906 |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
In vitro study | lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45 Ca influx with associated histamine release in purified rat peritoneal mast cells. |
In vivo study | Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep. |
anti-allergic agents, mainly eye drops, can also be used for oral formulations and aerosols, for bronchial asthma. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.805 ml | 9.027 ml | 18.054 ml |
5 mM | 0.361 ml | 1.805 ml | 3.611 ml |
10 mM | 0.181 ml | 0.903 ml | 1.805 ml |
5 mM | 0.036 ml | 0.181 ml | 0.361 ml |